Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use

Duffy, Michael J.; Dalen, A. van; Haglund, Caj; Hansson, Lars‐Erik; Holinski‐Feder, Elke; Klapdor, R; Lamerz, R.; Peltomäki, Païvi; Sturgeon, C.; Topolčan, Ondřej

doi:10.1016/j.ejca.2007.03.021

Cited by 527 publications

(504 citation statements)

References 88 publications

Supporting

Mentioning

469

Contrasting

Unclassified

Order By: Relevance

“…CEA wird in der Nachsorge in einer Literaturübersicht nicht empfohlen [1264]. Amerikanische (ASCO) und europäische (EGTM, European Group on Tumour Markers) Leitlinien zur Nachsorge enthalten jedoch das CEA [1263,1265,1267], wobei die Bestimmung alle 2 -3 Monate in den ersten 2 Jahren empfohlen wird.…”

Section: Hintergrundunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

148

View full text Add to dashboard Cite

Section: Hintergrundunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

148

View full text Add to dashboard Cite

“…The role of molecular tumour biomarkers in determining disease recurrence is also under investigation, but requires further validation. 5,6 In addition to intrinsic tumour factors, patient prognosis is also influenced by the host inflammatory response to malignancy, with data supporting a direct role for inflammatory cells and mediators in the promotion of both primary tumour growth and disease dissemination. 7,8 At the local level, the immune response involves infiltration of the tumour environment by both lymphocytes and cells of myeloid lineages.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases

Neal¹,

Mann²,

Sutton³

et al. 2009

European Journal of Cancer

View full text Add to dashboard Cite

Background: There is increasing evidence that the presence of a preoperative systemic inflammatory response (SIR) independently predicts poor long-term outcome in patients with colorectal cancer (CRC).Socioeconomic deprivation was reported to correlate with the presence of the SIR and to itself independently predict poor outcome following primary CRC resection. The aim of this study was to determine the prognostic value of preoperative systemic inflammatory biomarkers and socioeconomic deprivation in patients undergoing resection of colorectal liver metastases (CLM) and to examine correlations between these variables in this context. Results: On multivariable analysis, poor CRS (3-5), high neutrophil count (>6.0 x10 9 /L) and low serum albumin (<40 g/dL) were the only independent predictors of shortened overall survival following metastasectomy, with neutrophil count representing the greatest relative risk of death. These factors were also the only independent predictors of shortened disease-free survival 3 following hepatectomy. Socioeconomic deprivation was associated with neither systemic inflammation nor long-term outcome in this context. Patients and methods: Conclusions:The presence of a preoperative systemic inflammatory response, but not socioeconomic deprivation, independently predicts shortened survival following resection of CLM.4

show abstract

“…The issue of prognostic heterogeneity for patients with stage III colorectal cancer (Merkel et al, 2001) has, in part, been addressed by the last TNM edition, where colonic carcinoma patients are substaged according to the depth of the intestinal wall invasion and the number of lymph nodes involved (Greene et al, 2002). In this scenario, a large number of biomolecular markers have been suggested as new prognostic factors in locally advanced colonic carcinomas, but there are insufficient data or a poor clinical translation for most of them (Duffy et al, 2003;Funaioli et al, 2006).…”

mentioning

confidence: 99%

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

et al. 2007

View full text Add to dashboard Cite

Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in 162 (71%) tumours with a prevalence for right-sided tumours (Po0.001). Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas.

show abstract

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use

Cited by 527 publications

References 88 publications

S3-Leitlinie – Kolorektales Karzinom

S3-Leitlinie – Kolorektales Karzinom

Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

Contact Info

Product

Resources

About